JP6444321B2 - ヒト化主要組織適合性遺伝子複合体を発現するマウス - Google Patents

ヒト化主要組織適合性遺伝子複合体を発現するマウス Download PDF

Info

Publication number
JP6444321B2
JP6444321B2 JP2015558950A JP2015558950A JP6444321B2 JP 6444321 B2 JP6444321 B2 JP 6444321B2 JP 2015558950 A JP2015558950 A JP 2015558950A JP 2015558950 A JP2015558950 A JP 2015558950A JP 6444321 B2 JP6444321 B2 JP 6444321B2
Authority
JP
Japan
Prior art keywords
mhc
human
polypeptide
rodent
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015558950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016507247A5 (enExample
JP2016507247A (ja
Inventor
リン マクドナルド，
リン マクドナルド，
アンドリュー ジェイ． マーフィー，
アンドリュー ジェイ． マーフィー，
ベラ ボロニナ，
ベラ ボロニナ，
ケイガン ギュラー，
ケイガン ギュラー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50236326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6444321(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2016507247A publication Critical patent/JP2016507247A/ja
Publication of JP2016507247A5 publication Critical patent/JP2016507247A5/ja
Application granted granted Critical
Publication of JP6444321B2 publication Critical patent/JP6444321B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Preparation (AREA)
JP2015558950A 2013-02-22 2014-02-20 ヒト化主要組織適合性遺伝子複合体を発現するマウス Active JP6444321B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361767811P 2013-02-22 2013-02-22
US61/767,811 2013-02-22
PCT/US2014/017387 WO2014130667A1 (en) 2013-02-22 2014-02-20 Mice expressing humanized major histocompatibility complex

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018101501A Division JP6681939B2 (ja) 2013-02-22 2018-05-28 ヒト化主要組織適合性遺伝子複合体を発現するマウス

Publications (3)

Publication Number Publication Date
JP2016507247A JP2016507247A (ja) 2016-03-10
JP2016507247A5 JP2016507247A5 (enExample) 2017-03-23
JP6444321B2 true JP6444321B2 (ja) 2018-12-26

Family

ID=50236326

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015558950A Active JP6444321B2 (ja) 2013-02-22 2014-02-20 ヒト化主要組織適合性遺伝子複合体を発現するマウス
JP2018101501A Active JP6681939B2 (ja) 2013-02-22 2018-05-28 ヒト化主要組織適合性遺伝子複合体を発現するマウス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018101501A Active JP6681939B2 (ja) 2013-02-22 2018-05-28 ヒト化主要組織適合性遺伝子複合体を発現するマウス

Country Status (19)

Country Link
US (3) US10154658B2 (enExample)
EP (3) EP2958937B1 (enExample)
JP (2) JP6444321B2 (enExample)
KR (1) KR102211267B1 (enExample)
CN (2) CN110192541B (enExample)
AU (2) AU2014218893C1 (enExample)
CA (1) CA2900824A1 (enExample)
CY (1) CY1121223T1 (enExample)
DK (1) DK2958937T3 (enExample)
ES (3) ES2697248T3 (enExample)
HR (1) HRP20181866T1 (enExample)
HU (1) HUE041878T2 (enExample)
LT (1) LT2958937T (enExample)
PL (1) PL2958937T3 (enExample)
PT (1) PT2958937T (enExample)
RS (1) RS57963B1 (enExample)
SI (1) SI2958937T1 (enExample)
SM (1) SMT201800614T1 (enExample)
WO (1) WO2014130667A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201510056SA (en) 2011-10-28 2016-01-28 Regeneron Pharma Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
KR102295746B1 (ko) 2011-10-28 2021-09-01 리제너론 파아마슈티컬스, 인크. 유전자 변형된 주요 조직적합성 복합체 마우스
CA2900832A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
JP6444321B2 (ja) 2013-02-22 2018-12-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化主要組織適合性遺伝子複合体を発現するマウス
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
AU2014249148B2 (en) * 2013-03-11 2020-04-02 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
SMT202500280T1 (it) 2013-09-23 2025-09-12 Regeneron Pharma Animali non umani aventi un gene umanizzato della proteina regolatrice del segnale
TR201904342T4 (tr) 2013-10-15 2019-05-21 Regeneron Pharma Hümani̇ze il-15 hayvanlar
EP3071024B1 (en) 2013-11-19 2018-09-05 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
EP3430898A1 (en) 2013-11-19 2019-01-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
SMT202000332T1 (it) 2014-04-08 2020-07-08 Regeneron Pharma Animali non umani aventi recettori fc-gamma umanizzati
US9795121B2 (en) 2014-05-05 2017-10-24 Regeneron Pharmaceuticals, Inc. Humanized C3 animals
NO2785538T3 (enExample) 2014-05-07 2018-08-04
DK3157956T3 (da) 2014-06-19 2020-04-27 Regeneron Pharma Ikke-humane dyr med et humaniseret gen med programmeret celledød 1
KR20170083534A (ko) 2014-09-19 2017-07-18 리제너론 파마슈티칼스 인코포레이티드 키메라 항원 수용체
BR112017010793A2 (pt) 2014-11-24 2017-12-26 Regeneron Pharma animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo.
ES2969389T3 (es) 2014-12-05 2024-05-17 Regeneron Pharma Animales no humanos que tienen un gen del grupo de diferenciación 47 humanizado
EP4399969A3 (en) * 2014-12-09 2024-10-30 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
AU2016246698B2 (en) 2015-04-06 2022-06-02 Regeneron Pharmaceuticals, Inc. Humanized T cell mediated immune responses in non-human animals
PT3376857T (pt) 2015-11-20 2021-05-27 Regeneron Pharma Animais não humanos com um gene humanizado 3 de ativação de linfócitos
CA3014645C (en) 2016-02-29 2022-10-25 Regeneron Pharmaceuticals, Inc. Rodents having a humanized tmprss gene
IL263160B2 (en) 2016-06-03 2024-01-01 Regeneron Pharma Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
EP3585162B1 (en) 2017-09-29 2023-08-30 Regeneron Pharmaceuticals, Inc. Rodents comprising a humanized ttr locus and methods of use
JP7361031B2 (ja) 2017-11-30 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物
SMT202500038T1 (it) 2018-03-24 2025-03-12 Regeneron Pharma Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo
KR20250121150A (ko) 2018-03-26 2025-08-11 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
HUE067361T2 (hu) 2018-07-16 2024-10-28 Regeneron Pharma Ditra betegség rágcsáló modelljei és alkalmazásaik
AU2020253532B2 (en) 2019-04-04 2024-06-20 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized coagulation factor 12 locus
WO2020247452A1 (en) 2019-06-04 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
SG11202111256XA (en) 2019-06-07 2021-11-29 Regeneron Pharma Non-human animals comprising a humanized albumin locus
CN113105555B (zh) * 2020-01-10 2023-05-30 百奥赛图(北京)医药科技股份有限公司 Mhc分子人源化的非人动物的构建方法及应用
IL307238A (en) 2021-03-31 2023-11-01 Regeneron Pharma Transgenic mice containing human components of the cellular immune system with an enhanced diversity of the TCRB repertoire
CA3258639A1 (en) 2022-06-07 2023-12-14 Regeneron Pharma Multispecific molecules to modulate T lymphocyte activity, and their uses
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
EP4590120A1 (en) 2022-09-22 2025-07-30 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing components of human cellular immune system
US20250339384A1 (en) 2023-01-27 2025-11-06 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
TW202520975A (zh) 2023-08-09 2025-06-01 英商劍橋企業有限公司 基因改造之囓齒動物及囓齒動物細胞以及其等用途
WO2025064470A1 (en) 2023-09-19 2025-03-27 Regeneron Pharmaceuticals, Inc. Viral peptides and uses thereof
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025136809A2 (en) 2023-12-19 2025-06-26 Regeneron Pharmaceuticals, Inc. Foxp3 peptides and uses thereof
WO2025178991A1 (en) 2024-02-21 2025-08-28 Regeneron Pharmaceuticals, Inc. Splicing factor gene mutation-associated neoantigenic peptides and uses thereof

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
DE69033493D1 (de) 1989-07-25 2004-08-12 Cell Genesys Inc Homologe rekombination für universelle donorzellen und chimerische säugetierzellen
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5489742A (en) * 1990-10-23 1996-02-06 Board Of Regents, The University Of Texas System Transgenic rats and animal models of inflammatory disease
GB9100481D0 (en) 1991-01-10 1991-02-20 Inst Nat Sante Rech Med Genetically engineered mice
WO1993005817A1 (en) 1991-09-19 1993-04-01 President And Fellows Of Harvard College Transgenic mhc class i and class ii antigen-deficient mammals
EP0663952A4 (en) 1992-09-11 1997-06-11 Univ California Transgenic non-human animals having targeted lymphocyte transduction genes.
US5523226A (en) * 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
GB9315303D0 (en) 1993-07-23 1993-09-08 Zeneca Ltd Polypeptide
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
US6002066A (en) 1996-01-16 1999-12-14 Ortho Pharmaceutical Corp. H2-M modified transgenic mice
WO1997032603A1 (en) 1996-03-05 1997-09-12 The Scripps Research Institute Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
AU741130B2 (en) 1997-09-16 2001-11-22 Oregon Health Sciences University Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US6372955B1 (en) 1998-02-17 2002-04-16 Ortho Mcneil Pharmaceutical, Inc. Methods for Producing B cells and antibodies from H2-O modified transgenic mice
WO2000065058A1 (en) * 1999-04-23 2000-11-02 Pharmexa A/S Method for down-regulating il5 activity
WO2001027291A1 (en) 1999-10-12 2001-04-19 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
US20030124524A1 (en) 2000-06-23 2003-07-03 Kenneth Kornman Screening assays for identifying modulators of the inflammatory or immune response
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JPWO2002047474A1 (ja) 2000-12-13 2004-04-15 住友製薬株式会社 Ｈｌａ−ａ２４発現トランスジェニック動物及びその利用
WO2002059263A2 (en) 2000-12-19 2002-08-01 Sunol Molecular Corporation Transgenic animals comprising a humanized immune system
FR2827302B1 (fr) 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
US8895020B2 (en) 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
CA2522380A1 (en) 2003-03-19 2004-09-30 Isogenis, Inc. Specific inhibition of allorejection
SE0301109D0 (sv) * 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US7745690B2 (en) 2004-03-09 2010-06-29 Nagoya Industrial Science Research Institute Transgenic nonhuman mammal representing the pathologic conditions of human rheumatoid arthritis
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
GB0425713D0 (en) * 2004-11-23 2004-12-22 Baker Matthew Immunogencity testing and antibody selection methods
WO2007131092A2 (en) 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
EP1878798A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
HU0700534D0 (en) * 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
JP2008159109A (ja) 2006-12-21 2008-07-10 Matsushita Electric Ind Co Ltd データ転送装置
TWI476280B (zh) 2008-03-07 2015-03-11 Regeneron Pharma 來自二倍體宿主胚胎注射之ｅｓ－細胞衍生的老鼠
PT2708559T (pt) * 2008-04-11 2018-05-16 Chugai Pharmaceutical Co Ltd Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio
US20090328240A1 (en) 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
LT2346994T (lt) 2008-09-30 2022-03-10 Ablexis, Llc Knock-in pelė, skirta chimerinių antikūnų gamybai
EP3028565B1 (en) 2009-07-08 2017-09-27 Kymab Limited Animal models and therapeutic molecules
GB2472108B (en) 2009-08-27 2011-07-13 Budha Singh Dhinjan Wall bead
US8754287B2 (en) * 2009-12-10 2014-06-17 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
SMT201900372T1 (it) 2010-02-08 2019-09-09 Regeneron Pharma Topo con catena leggera comune
CN105218674A (zh) 2010-03-11 2016-01-06 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
KR102004106B1 (ko) 2010-03-31 2019-07-25 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
US9695410B2 (en) 2010-07-15 2017-07-04 Technion Research & Development Foundation Limited Isolated high affinity entities with T-cell receptor like specificity towards native complexes of MHC class II and glutamic acid decarboxylase (GAD) autoantigenic peptides
RU2580017C2 (ru) 2010-07-26 2016-04-10 Трианни, Инк. Трансгенные животные и способы применения
WO2012039779A1 (en) * 2010-09-24 2012-03-29 The United States Of America As Represented By The Secretary Of The Navy Humanized transgenic mouse model
RU2751240C2 (ru) 2011-10-28 2021-07-12 Регенерон Фармасьютикалс, Инк. Гуманизированные il-6 и рецептор il-6
KR102295746B1 (ko) * 2011-10-28 2021-09-01 리제너론 파아마슈티컬스, 인크. 유전자 변형된 주요 조직적합성 복합체 마우스
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
SG10201510056SA (en) 2011-10-28 2016-01-28 Regeneron Pharma Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
ES2748662T3 (es) 2012-11-05 2020-03-17 Institute For Res In Biomedicine Irb Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos
CA2900832A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
JP6444321B2 (ja) 2013-02-22 2018-12-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化主要組織適合性遺伝子複合体を発現するマウス
WO2014164640A1 (en) 2013-03-11 2014-10-09 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules
AU2014249148B2 (en) 2013-03-11 2020-04-02 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
JP2016520316A (ja) 2013-06-03 2016-07-14 テラベクティ ＭＨＣクラスＩ、ＭＨＣクラスＩＩまたはβ２ミクログロブリン上流プロモーター配列を含有するレンチウイルスベクター
WO2015056774A1 (ja) 2013-10-18 2015-04-23 大鵬薬品工業株式会社 Ｈｌａクラスｉ発現非ヒト動物
AU2016246698B2 (en) 2015-04-06 2022-06-02 Regeneron Pharmaceuticals, Inc. Humanized T cell mediated immune responses in non-human animals
IL263160B2 (en) 2016-06-03 2024-01-01 Regeneron Pharma Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
PL3720279T3 (pl) 2017-12-05 2023-01-16 Regeneron Pharmaceuticals, Inc. Myszy posiadające zmodyfikowany sposobami inżynierii łańcuch lekki lambda immunoglobuliny oraz ich zastosowania

Also Published As

Publication number Publication date
HUE041878T2 (hu) 2019-06-28
US20220201994A1 (en) 2022-06-30
AU2018271326A1 (en) 2018-12-20
KR102211267B1 (ko) 2021-02-04
CA2900824A1 (en) 2014-08-28
US20140245467A1 (en) 2014-08-28
WO2014130667A1 (en) 2014-08-28
AU2014218893A1 (en) 2015-09-10
AU2014218893C1 (en) 2019-03-07
HK1214613A1 (en) 2016-07-29
PL2958937T3 (pl) 2019-01-31
ES2949029T3 (es) 2023-09-25
KR20150122710A (ko) 2015-11-02
AU2018271326B2 (en) 2021-07-01
EP3699190A1 (en) 2020-08-26
JP2018126170A (ja) 2018-08-16
HRP20181866T1 (hr) 2019-01-25
US12414551B2 (en) 2025-09-16
ES2798751T3 (es) 2020-12-14
ES2697248T3 (es) 2019-01-22
CY1121223T1 (el) 2020-05-29
EP3699190B1 (en) 2023-06-07
JP6681939B2 (ja) 2020-04-15
EP3421490A1 (en) 2019-01-02
EP3421490B1 (en) 2020-04-01
EP2958937A1 (en) 2015-12-30
JP2016507247A (ja) 2016-03-10
US11224208B2 (en) 2022-01-18
CN110192541B (zh) 2022-02-18
US20190133095A1 (en) 2019-05-09
DK2958937T3 (en) 2018-11-26
EP3699190B9 (en) 2023-10-04
LT2958937T (lt) 2018-11-26
SMT201800614T1 (it) 2019-01-11
AU2014218893B2 (en) 2018-08-30
RS57963B1 (sr) 2019-01-31
PT2958937T (pt) 2018-11-27
EP3699190C0 (en) 2023-06-07
SI2958937T1 (sl) 2018-12-31
CN110192541A (zh) 2019-09-03
EP2958937B1 (en) 2018-08-15
US10154658B2 (en) 2018-12-18
AU2018271326C1 (en) 2022-01-13
CN105164154A (zh) 2015-12-16
CN105164154B (zh) 2019-06-07

Similar Documents

Publication Publication Date Title
US12414551B2 (en) Genetically modified major histocompatibility complex mice
US10314296B2 (en) Genetically modified major histocompatibility complex mice
KR101926442B1 (ko) 키메라 주요 조직적합성 복합체 （ｍｈｃ） ｉｉ 분자들을 발현하는 유전자 변형된 마우스
JP6456350B2 (ja) キメラ主要組織適合複合体（ｍｈｃ）クラスｉｉ分子を発現する遺伝子導入マウス
HK40036775A (en) Murine cell expressing humanized major histocompatibility complex
HK40036775B (en) Murine cell expressing humanized major histocompatibility complex
RU2797549C2 (ru) Генетически модифицированные мыши, экспрессирующие химерные молекулы главного комплекса гистосовместимости
HK40007414B (en) Method of generating non-human animals expressing humanized major histocompatibility complex
HK40007414A (en) Method of generating non-human animals expressing humanized major histocompatibility complex
HK1214613B (en) Mice expressing humanized major histocompatibility complex

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180528

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181029

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181127

R150 Certificate of patent or registration of utility model

Ref document number: 6444321

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250